NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.

CONCLUSIONS: The use of IMPT generally reduces the expected toxicity risk while maintaining good tumor coverage in the examined HNSCC patients. A mixed modality treatment using IMPT solely for a sequential boost reduces the risk by 10% only in rare cases. In contrast, pure IMPT treatment may be reasonable for about half of the examined patient cohort considering the toxicities xerostomia and dysphagia, if a feasible strategy for patient anatomy changes is implemented.
PMID: 26340301 [PubMed - as supplied by publisher]

Source: Acta Oncologica - September 4, 2015 Category: Cancer & Oncology Authors: Jakobi A, Stützer K, Bandurska-Luque A, Löck S, Haase R, Wack LJ, Mönnich D, Thorwarth D, Perez D, Lühr A, Zips D, Krause M, Baumann M, Perrin R, Richter C Tags: Acta Oncol Source Type: research